Home » Authors » Anette Breindl

Articles by Anette Breindl

Teaming Up With Myosin Gains Phagosomes Entry Into Nucleus

Aug. 23, 2007

By Anette Breindl

Teaming Up With Myosin Gains Phagosomes Entry Into Nucleus

Aug. 23, 2007

By Anette Breindl

Relationship Of Aneuploidy To Growth, Cancer Risk "Complex"

Aug. 20, 2007

By Anette Breindl

Relationship Of Aneuploidy To Growth, Cancer Risk "Complex"

Aug. 20, 2007

By Anette Breindl

New Glaucoma Approaches Go Beyond Taking The Pressure Off

Aug. 16, 2007

By Anette Breindl

New Glaucoma Approaches Go Beyond Taking The Pressure Off

Aug. 16, 2007

By Anette Breindl

To Fight Autoimmunity, Prevent Immune System One-Two Punch

Aug. 14, 2007

By Anette Breindl

To Fight Autoimmunity, Prevent Immune System One-Two Punch

Aug. 14, 2007

By Anette Breindl

Rational Vaccine Design Aims For Optimal Immune Response

Aug. 13, 2007

By Anette Breindl

Rational Vaccine Design Aims For Optimal Immune Response

Aug. 13, 2007

By Anette Breindl

Popular Stories

Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
Innervation can slow, as well as speed, tumor growth, study finds
BioWorld
Innervation by the sympathetic nervous system is typically a boon to tumors. But researchers from Weill Cornell Medicine and colleagues have shown that in some...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.